Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline

 
• By David Wild

Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.

Soft and blurry image:Medical image MRI Brain showing There is diameter cystic mass or tumor at Left frontal lobe Glioblastoma at Lt frontal lobe with metastasis, brain metastases.
Biopharma Investments Offer Hope For Glioblastoma Patients • Source: Shutterstock

Patients with glioblastoma can expect to live a median eight months after diagnosis, but two anticipated launches in 2024 and a rich development pipeline could improve that bleak clinical outlook.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo